Pik3ca mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer

Clinical Cancer Research

Volumn 20, Issue 22, 2014, Pages 5823-5834

  Markou, Athina ^a   Farkona, Sofia ^a   Schiza, Christina ^a   Efstathiou, Tonia ^a   Kounelis, Sophia ^b   Malamos, Nikos ^b   Georgoulias, Vassilis ^c   Lianidou, Evi ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 19; DOCETAXEL; DOUBLE STRANDED DNA; EPIRUBICIN; EPITHELIAL CELL ADHESION MOLECULE; MESSENGER RNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST CANCER CELL LINE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EARLY CANCER; EXON; GENE EXPRESSION; HIGH RESOLUTION MELTING ANALYSIS; HOTSPOT MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PIK3CA GENE; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; BREAST NEOPLASMS; CANCER STAGING; CASE CONTROL STUDY; DISEASE COURSE; FEMALE; GENETICS; METABOLISM; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR CELL LINE; TUMOR EMBOLISM; TUMOR RECURRENCE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84916898794     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0149     Document Type: Article

References (52)

1. Pantel K, Alix-Panabi -eres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009;6:339-51.
2. Lianidou ES, Mavroudis D, Georgoulias V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer 2013;108:2426-32.
3. Plaks V, Koopman C, Werb Z. Circulating Tumor Cells. Science 2013; 341:1186-8.
4. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002;20: 3404-12.
5. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, et al.Predictive and prognostic value of peripheral blood cyto-keratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006;24:3756-62.
6. Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 2007;18:1623-31.
7. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009;27:2177-84.
8. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010;21:729-33.
9. Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, et al. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res 2011;13:R60.
10. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012;13:688-95.
11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2014;351:781-91.
12. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011;13:R67.
13. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009;115:581-90.
14. Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012;23:618-24.
15. Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, et al. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Br J Cancer 2012;106:1917-25.
16. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Metaanalysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012;18:5701-10.
17. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabi -eres C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013;32:179-88.
18. Lianidou ES, Markou A, Strati A. Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer Metastasis Rev 2012;31: 663-71.
19. Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulias V, et al. Gene expression pro file of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 2011;11:422.
20. Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 2011;57: 421-30.
21. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11:R46.
22. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009;118:455-68.
23. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 2011;57:1169-77.
24. Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem 2013;59:270-9.
25. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
26. Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, et al.KRASand BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013;133:130-41.
27. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013;59:252-60.
28. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013;73: 2965-75.
29. Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, et al. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 2013;7: 976-86.
30. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasmaDNA. Sci TranslMed 2012;4:136ra68.
31. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462-9
32. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, et al. PIK3CA mutation impact on survival in breast cancer patients and in ERa, PR and ERBB2-based subgroups. Breast Cancer Res 2012;14:R28.
33. Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 2013;108: 1807-9.
34. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sanchez V, et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A 2013;110:14372-7.
35. Martini M, Ciraolo E, Gulluni F, Hirsch E. Targeting PI3K in cancer: any good news? Front Oncol 2013;3:108.
36. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi T, Zhang AH, Chen AH, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010;2:43ra55.
37. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012;7: e33788
38. Zhou L, Wang Y, Wittwer CT. Rare allele enrichment and detection by allele-specific PCR, competitive probe blocking, and melting analysis. BioTechniques 2011;50:311-8.
39. Berry CC. The kappa statistic. JAMA 1992;268:2513.
40. Castellanos-Rizaldos E, Liu P, Milbury CA, Guha M, Brisci A, Cremonesi L, et al. Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment. Clin Chem 2012; 58:1130-8.
41. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES. PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J Mol Diagn 2010;12:697-704.
42. Ang D, O'Gara R, Schilling A, Beadling C, Warrick A, Troxell ML, et al. Novel method for PIK3CA mutation analysis: locked nucleic acid-PCR sequencing. J Mol Diagn 2013;15:312-8.
43. Harl -e A, Lion M, Lozano N, Husson M, Harter V, Genin P, et al. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria. Oncol Rep 2013;29:1043-52.
44. Kitano S, Myers J, Nakamura J, Yamane A, Yamashita M, Nakayama M, et al. A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PLoS ONE 2013;8:e62989.
45. Patel R, Tsan A, Tam R, Desai R, Schoenbrunner N, Myers TW, et al. Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel. PLoS ONE 2012;7:e51153.
46. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients withKRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:143-50.
47. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-91.
48. Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, et al. Detection and recovery of circulating colon cancer cells using a dielectrophor-esis-based device: KRAS mutation status in pure CTCs. Cancer Lett 2013;335:225-31.
49. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, et al. In fluence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012;30:3077-83.
50. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18: 6373-83.
51. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemother-apy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol 2012;23:1744-50.
52. Donovan CA, Pommier RF, Schillace R, O'Neill S, Muller P, Alabran JL, et al. Correlation of breast cancer axillary lymph node metastases with stem cell mutations. JAMA Surg 2013;148:873-8.